Schiffrin EL. Hypertension: treatments, diabetes, and developing regions. Lancet 2012; 380: 539–541.
Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet 2012; 380: 611–619.
Hu DY, Liu LS, Yu JM, Yao CH. National survey of blood pressure control rate in Chinese hypertensive outpatients-China STATUS. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 230–238.
Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372.
National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–1133.
Tocci G, Battistoni A, Passerini J, Musumeci MB, Francia P, Ferrucci A et al. Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther 2015; 20: 121–130.
Zhu DL, Gao PJ, Holtbruegge W, Huang CL. A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients. J Int Med Res 2014; 42: 52–66.
Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 2012; 59: 1132–1138.
Lu Z, Chen Y, Li L, Wang G, Xue H, Tang W. Combination therapy of renin-angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. J Hum Hypertens, (e-pub ahead of print 7 January 2016; doi:10.1038/jhh.2015.125).
Chi C, Tai C, Bai B, Yu S, Karamanou M, Wang J et al. Angiotensin system blockade combined with calcium channel blockers is superior to other combinations in cardiovascular protection with similar blood pressure reduction: a meta-analysis in 20451 hypertensive patients. J Clin Hypertens (Greenwich), (e-pub ahead of print 17 January 2016; doi:10.1111/jch.12771).
Ma J, Wang XY, Hu ZD, Zhou ZR, Schoenhagen P, Wang H. Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a calcium channel blocker (CCB) following ineffective CCB monotherapy. J Thorac Dis 2015; 7: 2243–2252.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg 2000; 87: 1448–1454.
Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions: cochrane Book Series. John Wiley & Sons: Chichester, UK, 2008.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926.
Andreadis EA, Tsourous GI, Marakomichelakis GE, Katsanou PM, Fotia ME, Vassilopoulos CV et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005; 19: 491–496.
Andreadis EA, Sfakianakis ME, Tsourous GI, Georgiopoulos DX, Fragouli EG, Katsanou PM et al. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness. Int Angiol 2010; 29: 266–272.
Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A et al. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opin Drug Saf 2013; 12: 621–629.
Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res 2014; 8: HC08–HC11.
Kang SM, Youn JC, Chae SC, Park CG, Yang JY, Kim MH et al. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study. Clin Ther 2011; 33: 1953–1963.
Lee H-Y, Kim Y-J, Ahn T, Youn H-J, Chull Chae S, Seog Seo H et al. A randomized, multicenter, double-blind, placebo-controlled, 3 × 3 factorial design, phase II study to evaluate the efficacy and safety of the combination of fimasartan/amlodipine in patients with essential hypertension. Clin Ther 2015; 37: 2581–2596.e2583.
Lin TH, Tsai CD, Pan JP, Hou CJY, Hsia CH, Tsai JP et al. Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. Kaohsiung J Med Sci 2013; 29: 265–270.
Littlejohn TW III, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R et al. Original research: telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. Postgrad Med 2009; 121: 5–14.
Neldam S, Lang M, Jones R. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens (Greenwich) 2011; 13: 459–466.
Park CG, Youn HJ, Chae SC, Yang JY, Kim MH, Hong TJ et al. Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. Am J Cardiovasc Drugs 2012; 12: 35–47.
Schrader J, Salvetti A, Calvo C, Akpinar E, Keeling L, Weisskopf M et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract 2009; 63: 217–225.
Park JB, Ha JW, Jung HO, Rhee MY. Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study. Blood Press Monit 2014; 19: 294–301.
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11000 participants from 42 trials. Am J Med 2009; 122: 290–300.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–520.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Blood Press 2013; 22: 193–278.
Caballero-Gonzalez FJ. Calcium channel blockers in the management of hypertension in the elderly. Cardiovasc Hematol Agents Med Chem 2015; 12: 160–165.
Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312–320.
Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 2010; 15: 195–204.
Ke Y, Zhu D, Hong H, Zhu J, Wang R, Cardenas P et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin 2010; 26: 1705–1713.
Xu R, Sun S, Huo Y, Yun L, Huang S, Li G et al. Effects of ACEIs versus ARBs on Proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials. Medicine (Baltimore) 2015; 94: e1560.
Murthy MB, Murthy B. Amlodipine-induced petechial rash. J Postgrad Med 2011; 57: 341–342.
Tuchinda P, Kulthanan K, Khankham S, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to calcium channel blockers. Asian Pac J Allergy Immunol 2014; 32: 246–250.